3--hydroxybenanomicin-a and Fungemia

3--hydroxybenanomicin-a has been researched along with Fungemia* in 1 studies

Other Studies

1 other study(ies) available for 3--hydroxybenanomicin-a and Fungemia

Article	Year
In vitro antifungal activity of BMS-181184 against systemic isolates of Candida, Cryptococcus, and Blastomyces species. Diagnostic microbiology and infectious disease, 1997, Volume: 28, Issue:4 BMS-181184 is a water-soluble derivative of the pradimicin group of antifungal compounds. We determined the in vitro activities of BMS-181184 and comparator agents amphotericin B, 5-fluorocytosine, fluconazole, and ketoconazole against 184 systemic fungal isolates collected at the Health Sciences Centre in Winnipeg, Canada, between 1987 and 1995. BMS-181184 demonstrated MICs of between 1 and 8 micrograms/mL for all Candida albicans, Candida glabrata, Candida tropicalis, Candida krusei, Candida lusitaniae, and Cryptococcus neoformans isolates tested. BMS-181184 was less active against Candida parapsilosis (MIC90 = 16 micrograms/mL) and Blastomyces dermatitidis (MIC90 = 32 micrograms/mL). Isolates of Candida species with fluconazole MICs of > or = 16 micrograms/mL and those with fluconazole MICs of < or = 8 micrograms/mL demonstrated similar BMS-181184 sensitivities. Topics: Anthracyclines; Antibiotics, Antineoplastic; Antifungal Agents; Blastomyces; Blastomycosis; Candida; Candidiasis; Cryptococcosis; Cryptococcus; Drug Resistance, Microbial; Fungemia; Humans; Microbial Sensitivity Tests	1997

Article

Year

In vitro antifungal activity of BMS-181184 against systemic isolates of Candida, Cryptococcus, and Blastomyces species.

Diagnostic microbiology and infectious disease, 1997, Volume: 28, Issue:4

BMS-181184 is a water-soluble derivative of the pradimicin group of antifungal compounds. We determined the in vitro activities of BMS-181184 and comparator agents amphotericin B, 5-fluorocytosine, fluconazole, and ketoconazole against 184 systemic fungal isolates collected at the Health Sciences Centre in Winnipeg, Canada, between 1987 and 1995. BMS-181184 demonstrated MICs of between 1 and 8 micrograms/mL for all Candida albicans, Candida glabrata, Candida tropicalis, Candida krusei, Candida lusitaniae, and Cryptococcus neoformans isolates tested. BMS-181184 was less active against Candida parapsilosis (MIC90 = 16 micrograms/mL) and Blastomyces dermatitidis (MIC90 = 32 micrograms/mL). Isolates of Candida species with fluconazole MICs of > or = 16 micrograms/mL and those with fluconazole MICs of < or = 8 micrograms/mL demonstrated similar BMS-181184 sensitivities.

Topics: Anthracyclines; Antibiotics, Antineoplastic; Antifungal Agents; Blastomyces; Blastomycosis; Candida; Candidiasis; Cryptococcosis; Cryptococcus; Drug Resistance, Microbial; Fungemia; Humans; Microbial Sensitivity Tests

1997